3 Bio-Pharmaceuticals You Can’t Ignore: Arena Pharmaceuticals, Inc. (ARNA), VIVUS Inc. (VVUS)

Page 1 of 2

The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including the Amex Biotechnology Index ETF (FBT), the SPDR S&P Biotech ETF (XBI) and iShares NASDAQ Biotechnology Index (IBB), giving returns of more than 20%. The entire industry is heavily dependent for growth on the approvals of the Food and Drug Administration (FDA). According to research by Bloomberg, this year the authority approved the most number of drug candidates in the last fifteen years. The FDA usually approves around 20-25 drugs every year, but this year an exceptional 39 drugs received the FDA nod.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

A number of micro/small-cap bio-pharmaceutical companies have benefited from FDA approvals in the last couple of years, and amongst them are Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amarin Corporation plc (ADR) (NASDAQ:AMRN) and VIVUS, Inc. (NASDAQ:VVUS). These companies have since seen depreciating stock prices due to their inability to convert promise into actual fundamental value. Despite investor backlash, I believe these stocks are worth following and still hold value for investors.

Amarin

Amongst the 3 stocks under discussion today, Amarin is the safest and surest bet. The company has received FDA approval for its Triglyceride lowering drug Vascepa, but is still waiting for a decision on its NCE status. This decision has been the primary hindrance to a much anticipated acquisition of the company and has forced the company management to commercialize Vascepa. Amarin looks to upset GlaxoSmithKline’s Lovaza, which generates sales of approximately a billion dollars every year. What makes Vascepa exciting is the fact that unlike Lovaza, Vascepa also decreases LDL levels. The increase in LDL has been one of the primary reason physicians have been somewhat reluctant to prescribe Lovaza. With this restriction removed, the sales potential of Vascepa can be huge.

Vivus

The large number of FDA approvals also included two obesity control drugs: Qsymia and Belviq. Qsymia has been approved for chronic weight management in addition to reduced calorie diet and exercise. The initial sales data for Qsymia has not been good, but recent reports show that Qsymia has started to gain some momentum. Company disclosures show that Qsymia sales have shown a growth of 68%, and there is a strong expectation that this growth might continue.

Recent research also indicates that use of Qsymia leads to improvements in blood pressure, triglycerides, and cholesterol of obese patients suffering from these issues. This can be another incentive for doctors who have been so far hesitant to prescribe Qsymia due to its after-effects. Despite these setbacks, there is little doubt that Vivus still has a lot of potential, especially considering the obesity epidemic in the United States.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!